Been here since 2017.
Helped grow projects from 0 → billions MC.
Built communities, wrote Gitbooks, hosted Spaces.
Next chapter: scaling meme culture & communities that stick.
📢 Immunic will participate in key conferences this June, engaging with the #investor, #industry and #scientific communities.
💼 June 15-16 | H.C. Wainwright Neuro Perspectives Expert Summit (New York & virtual): Erik Lundgren, CEO, and Jason Tardio, President & COO, will participate in a #fireside chat. The presentation will be available via the conference platform and on #Immunic’s IR website.
🌐 June 22-25 | BIO International Convention (San Diego): Members of our management team will participate in #partnering activities.
🔬 June 22-25 | #EFMC-#ACSMEDI Medicinal #Chemistry Frontiers Symposium (Dublin): Dr. Christian Gege, Global Head of #IntellectualProperty, will present work related to #IMU856.
🧠 June 27-30 | European Academy of #Neurology (#EAN) Congress (Geneva): Members of our medical team will be present at #booth E42.
👉 View all details here: https://t.co/MMXfhVuVS4
$IMUX @HCWCO, @IAmBiotech, @EANeurology
Ticker: $IMUX (Immunic Inc.)
Alpha (Bullish Case)
IMUX secured up to $400M in financing, extending runway through 2027 and funding its Phase 3 ENSURE trials in relapsing MS, with top-line data expected by year-end 2026. That removes immediate funding risk and supports its transition toward becoming a commercial-stage biotech.
Technically, price launched from the strong demand zone around $0.50–$0.55 and impulsed into the $1.15–$1.20 supply zone before pulling back toward equilibrium near $0.90. If price holds above that equilibrium area and reclaims $1.00 with strength, a retest of $1.15–$1.20 is likely.
A clean break above supply could open a larger continuation move. Momentum expanded strongly on the breakout, supporting the impulsive structure.
Beta (Risk Case)
This is still a clinical-stage biotech, and valuation ultimately depends on Phase 3 results due late 2026. The sharp rejection from the supply zone suggests near-term exhaustion, and momentum is cooling. If price loses the $0.85–$0.90 equilibrium zone,
downside risk increases toward $0.70–$0.75, with the broader demand zone near $0.55 below that. Failure to hold those levels would suggest this was primarily a news-driven spike rather than the start of a sustained trend.
🔊 Today, we reported our year-end 2025 #FinancialResults and a #CorporateUpdate. Key highlights include:
🔬 Top-line data from our phase 3 #ENSURE trials in relapsing #MultipleSclerosis (#RMS) expected by year-end 2026
💰 $200 million raised in a private placement, with the potential for up to an additional $200 million
Net proceeds expected to fund:
• Completion of the phase 3 ENSURE trials
• Initiation of a phase 3 trial in primary progressive MS (#PPMS)
• Begin transition into a commercial-stage organization
🚀 With a strengthened financial position and important clinical milestones ahead, we believe 2026 could represent a defining period for the $IMUX team and, specifically, our late-stage MS development pipeline.
👉 Get all the details here: https://t.co/wMZEkoScke
#Immunic #FinancialResults #MSResearch #biotech #vidofludimus #IMU838